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We are pleased to present peer reviewed forum proceedings of
the 2nd synchronicity forum of GHRI/CHVIfunded Canadian and
African HIV prevention and vaccine teams
Forum objectives
 GHRI-funded capacity building and HIV prevention research
teams presented highlights of achievements
 Teams discussed how to jointly build on achievements for
sustainability
 Provided an opportunity for inter-team collaboration,
synchronize best approach to capacity building, mentoring of
new researchers and building leadership
 Provided opportunities for informal discussions and networking
among the teams.
 Teams learnt about recent advances in the area of African
regulatory and ethics review process
 The forum proceedings was a special supplement in an open-
access journal was produced
Forum partners
 Canada-Africa Prevention Trials (CAPT) Network
 TanZamBo Project
 Kenya AIDS Vaccine Initiative (KAVI)
 Nigerian HIV/AIDS Prevention Platform
 African Development of AIDS Prevention Trials (ADAPT2)
 Canada-Sub Saharan Africa HIV/AIDS Network (CanSSA)
 The Benin HIV prevention preparatory Team
 The Free State HIV prevention Team (SA)
 West African Platform for HIV Intervention Research (WAPHIR)
Funding and supporting partners
The Afri-Can Forum-2 was made possible by support grant from Canada’s
Global Health Research Initiative (GHRI), a partnership of Canadian gov-
ernment agencies dedicated to generating research that is relevant to
health and health system decision-making in developing countries.
GHRI partnership is composed of the Canadian Institutes of Health
Research (CIHR), Foreign Affairs, Trade and Development Canada
(DFATD), and the International Development Research Centre (IDRC).
Another important supporting partner in this Forum was the Alliance
Coordinating Office (ACO) of the Canadian HIV Vaccine Initiative (CHVI)
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Message from the chairs
Participants were all welcomed to the second special synchronicity
forum of the Afri-Can partnership (Canadian-African partnership on
capacity building in HIV prevention and intervention research), sup-
ported by Canada’s Global Health Research Initiative (GHRI). The Afri-
can teams in this partnership comprised of 9 research networks,
which collaborated closely with Canadian researchers that have
established excellence in HIV prevention research in African-owned
health institutions, enabled locally relevant research, high quality
training programs and strengthened capacity for HIV clinical trials.
This meeting took stock of our achievements, shared successes, fostered
inter-team collaboration and discussed ways to build on our experi-
ences. The meeting was timely when all of the GHRI-funded programs
came to a close before the 1st of December 2014; further posing a fun-
damental challenge on how to sustain what was built in the present glo-
bal climate of dire scarce research funding. We needed not only to
maintain our Institutional infrastructure and capacity but, expand our im-
pact to fundamentally change the HIV health research landscape in Af-
rica and maintain research excellence for generations to come.
This is a challenge that all of us including funders require giving
utmost commitment if we have to make the HIV pandemic history.
Everyone that participated in this Forum was committed to this chal-
lenge. We thank the participants for all their effort and participation
in the event.
Sincerely,
Assan Jaye DVM, PhD.
Chair, Planning Committee
Janan Dietrich MA, PhD,
Co-Chair, Planning Committee
Clive Gray MSc, PhD
Co-Chair, Planning Committee
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Theme 1: Behavioral and Social Approaches to
Prevention – BeSo
O1
Voluntary medical male circumcision for prevention of
heterosexual transmission of HIV in adult males in Soweto: What
do indicators and incidence rate show?
Hillary Mukudu1, Janan Dietrich1, Neil Martinson1, Benn Sartorius2
1Perinatal HIV Research Unit (PHRU), Chris Hani-Baragwanath Academic
Hospital, Johannesburg, South Africa, 2Department of Public Health
Medicine, School of Nursing and Public Health, University of KwaZulu
Natal, Durban, South Africa
Correspondence: Hillary Mukudu (mukuduh@phru.co.za) – Perinatal
HIV Research Unit (PHRU), Chris Hani-Baragwanath Academic Hospital,
Johannesburg, South Africa
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Background: The biomedical prevention of HIV transmission that med-
ical male circumcision confers was confirmed by three clinical trial set-
ting and then rolled out in VMMC programs in sub-Saharan Africa. Data
assessing the effectiveness of this under programmatic conditions is not
available. Concerns about possible risk compensation in circumcised
males after circumcision have been raised.
Methods: A cohort of 233 HIV seronegative adult males aged 18-40
years seeking circumcision at a public hospital were followed up for a
period ranging from 161 to 765 days after which the HIV serostatus rate
was ascertained. We also compared the HIV behavioral risk factors be-
fore and after circumcision by calculating odds ratio (OR) with the 95 %
confidence interval and p-value using the McNemar’s test. Logistic re-
gression was used to determine the predictors of proxy HIV risk, before
and after circumcision.
Results and Discussions: HIV incidence post circumcision 2.64 (95 % CI
0.54 - 4.75) per 100 person years. No evidence of risk compensation post
circumcision. However, the participants were almost three times (OR 2.7
95%CI 1.34-5.69, p = 0.003) more likely to have vaginal sexual intercourse
after circumcision, attributable to the fact that 21 % had either their sex-
ual debut after circumcision or did not have sexual intercourse in the six
months before circumcision but after. Post-circumcision there was evi-
dence of adoption of positive HIV prevention behaviour because partici-
pants were 3.5 times (OR = 3.5 95 % CI 1.88-7.14, p = <0.0001) more
likely to perceive themselves to be at risk of HIV and 58 % (OR = 0.42
95 % CI 0.16-1.01, p = 0.05) less likely to use alcohol with sex after cir-
cumcision. After circumcision participants in the 25-40 years age group
were more than two and a half times (OR 2.60 95%CI 1.14-5.91 p =
0.023) more likely to be at risk of HIV acquisition than those in the 18-24
years age group.
Conclusion: These findings underscore the effectiveness of medical male
circumcision in a program setting not only as a biomedical but also as a
behaviour change intervention for prevention of HIV transmission and
that there is no evidence of risk compensation after circumcision.
O2
Developing a peer-led community mobilization program for sex
workers in Soweto: HIV risk and demographics
Jenny Coetzee1,2, Janan Dietrich1, Kgaugelo Mokgatswana1,
Rachel Jewkes2, Glenda E Gray1,2
1Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto,
South Africa; 2Medical Research Council of South Africa, Cape Town,
South Africa
Correspondence: Jenny Coetzee (coetzeej@phru.co.za) – Perinatal HIV
Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa
BMC Infectious Diseases 2016, 16(Suppl 2):O2
Background: Sex work (SW) is illegal in South Africa making access to
health and legal services challenging. In 2014 the South African National
Aids Council launched a strategy to improve SW access to services. Prior
to September 2013, no SW programme existed in Soweto, a townshipon the outskirts of Johannesburg, despite SW activities in the more than
600 drinking establishments.
Methods: We aimed to work across Soweto collecting data to moni-
tor the development of a peer-led SW project. SW peer educators
(PEs)(n = 10) were trained to provide health talks, take field notes,
demonstrate and distribute condoms and complete fieldwork forms
during daily outreach, and to conduct HIV counselling and testing
(HCT) as part of a wellness check offered through an existing HCT
Centre (using non-SW lay counsellors and nurses). Data recorded in-
cluded the number of unique SWs contacted, contextual dynamics,
HIV results, CD4 count (laboratory), and referral for termination of
pregnancy. Between October 2013 and December 2014, 341 SWs
used the clinic services, 328 undertook HCT. In July 2014 we imple-
mented a peer-led HCT strategy. Ethical approval was obtained.
Results and Discussions: The age range for SWs was 18-69 years
(median 34). They were tavern and hostel based. Overall HIV positiv-
ity was 42 %, with outreach data suggesting that many SWs already
knew their HIV positive status and were either on treatment or
defaulting treatment. Service users preferred to undertake HCT
through our peer-led strategy (90 %). Uptake of CD4 counts was
poor (n = 63,46 %; CD4 range 37-2047, median 449) due to the non-
SW nurse, delays in patient flow and result delivery. In 12 months
we infiltrated 4/38 suburbs, with >3500 predominantly female SWs
accessing outreach services.
Conclusions: HIV prevalence may be higher than 42 % given that
outreach data suggests many SWs already know their status and thus
refuse the clinic services offered by PE. Treatment and prevention ad-
herence mechanisms need to be explored. Peer-led HCT to encour-
age HIV testing amongst SWs is a promising approach to SW
programming in South Africa, although this could be scaled up to in-
clude point-of-care testing in addressing the poor uptake of CD4
counts. Understanding the broader needs of this population is critical
to continued tailoring of key populations’ programmes.
O3
Salient beliefs about adherence: A qualitative survey conducted as
part of the demonstration study on "treatment as prevention"
(TasP) and "pre-exposure prophylaxis" (PrEP) among female sex
workers (FSWS) in Cotonou, Benin
Marylène Dugas, Luc Béhanzin, Fernand A. Guédou, Marie-Pierre
Gagnon, Michel Alary
Université Laval, Québec, Canada
Correspondence: Marylène Dugas (dugas11@hotmail.com) – Université
Laval, Québec, Canada
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Background: Among the strategies that have demonstrated good po-
tential to reduce the spread of HIV among FSWs are the preventive
methods TasP and PrEP. While these strategies have proven effective in
randomized controlled trials, their applications in natural context is less
convincing because, among other things, of therapeutic adherence. This
presentation concerns the results of a qualitative survey conducted on
the salient modal beliefs (Theory of Planned behavior) related to thera-
peutic adherence and conducted as part of a demonstration and feasi-
bility study of TasP and PrEP strategies in Cotonou, Benin.
Methods: The qualitative study was conducted among three types of
FSWs: 1- HIV Positive under antiretroviral (ARV) treatment; 2- HIV Positive
not under ARVs (CD4 > 350); 3- seronegative. The topics investigated
during the semi-structured interview were: 1- Advantages and disadvan-
tages of treatment adherence; 2- Normative aspects of the adherence;
3- Control of therapeutic adherence. The method of Gagné and Godin
(1999) was used for the evaluation and analysis.
Results and Discussions: A total of 31 FSWs participated in this study.
Regaining or maintaining health and enjoy protection against HIV were
the most cited advantages. The main disadvantages were: side effects,
the daily intake and, for infected women, having to take the medication
for life. On the normative aspects, the majority of FSWs have cited the
health care workers and other FSWs as the ones who would be most in
favor of adherence, except for other FSWs who would have experienced
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favor a good adhesion behavior, FSWs cited the efficient supply of ARVs
and food availability. For the component impeding adherence: the side
effects or lack of positive effects, the travels or the fear that the HIV sta-
tus is revealed by the possession of the tablets.
Conclusions: The results highlighted the most important elements for the
adhesion behavior of FSWs in Cotonou and allowed the creation of train-
ing tools for therapeutic adherence, which take into account these beliefs,
and allowed the development of a questionnaire for the following evalu-
ation of adherence behavior during TasP / PrEP demonstration study.
O4
Relative perception of risk as a driver of unsafe sexual practices
among key populations: Cases of fisherfolk and women and their
partners involved in multiple sexual partnerships in Uganda
Rwamahe Rutakumwa, Martin Mbonye, Thadeus Kiwanuka, Sarah
Nakamanya, Richard Muhumuza, Winfred Nalukenge, Janet Seeley
Medical Research Council/UVRI Uganda Research Unit on AIDS, Uganda
Correspondence: Rwamahe Rutakumwa (Rutakumwa@mrcuganda.org) –
Medical Research Council/UVRI Uganda Research Unit on AIDS, Uganda
BMC Infectious Diseases 2016, 16(Suppl 2):O4
Background: Fisherfolk and city-based women involved in multiple sex-
ual partnerships in Uganda face an increased risk of HIV. However, the
literature on how individuals make decisions about risk and sexual part-
ners is limited. We investigate the social construction of risk in order to es-
tablish how individuals prioritise a given risk based on its perceived threat.
Methods: Over a seven month period ending in January 2014, a qualitative
study was conducted among fisherfolk around Lake Victoria, and women
at high risk of HIV infection and their male partners in Kampala, Uganda.
We purposively sampled and held repeat life history in-depth interviews
with 50 (20 male and 30 female) participants; approximately half of these
were from each of the two study sites. Data were analysed thematically by
identifying and linking patterns and themes.
Results and Discussions: Fishermen feared drowning, and immedi-
ately on their return from fishing, they said they often engage in sex
usually with sex workers to ‘cool off’, suggesting that the threat of
HIV was perceived as less significant than drowning, and that sex has
therapeutic qualities. Partners of fishermen expressed a constant fear
of catching HIV because their men were promiscuous. However,
these women chose to stay with their men because the risk of pov-
erty arising from leaving their men was a bigger threat to them and
their children. Women engaged in commercial sex reported spousal
violence and lack of basic necessities as key motivators of their deci-
sion to leave their spouses, which through the lack of alternatives
led them into sex work. Misconceptions about the risk of condom use,
such as the fear of a condom breaking and disappearing inside a woman,
led to a preference for sex without a condom by some women.
Conclusions: An individual’s perception of risk is in some contexts con-
tingent upon her/his sense of other risks that they encounter in their
daily life. A risk where the consequence is perceived as being far away
may be considered less significant than more immediate threats. Atten-
tion to context specific perceptions of contingency of risk should
be paid in the design of interventions that promote safe sex.O5
Exploring the acceptability of new biomedical HIV prevention
technologies among MSM, adolescents and heterosexual adults in
South Africa
Millicent Atujuna, Melissa Wallace, Ben Brown, Linda Gail Bekker, Peter A.
Newman
Desmond Tutu Foundation, University of Cape Town, Cape Town, South
Africa
Correspondence: Millicent Atujuna (Millicent.atujuna@hiv-
research.org.za) – Desmond Tutu Foundation, University of Cape Town,
Cape Town, South Africa
BMC Infectious Diseases 2016, 16(Suppl 2):O5Background: Efforts to combat the transmission of HIV continue with nu-
merous biomedical prevention trials reporting varying levels of partial effi-
cacy. While these interventions offer promise for HIV prevention, their
success will hinge on their acceptability, particularly across various social
contexts. South Africa, hardest hit by the HIV epidemic, is of particular
interest as it grapples with the outcomes of a complex interaction between
issues of race, gender and migration created by apartheid, as they play out
in a changing political economy. In light of this, we examine the accept-
ability of a Vaccine, Microbicides and oral PrEP in three target groups,
namely adolescents (15-17 years), heterosexual adults and MSM.
Methods: We present qualitative data from populations recruited from two
communities in Cape Town. We conducted 6 focus groups (FGs) (5-9 par-
ticipants per group N = 36) and 12 in-depth interviews (IDIs). Of these, we
purposively conducted 2 FGs and 5 IDIs with participants naïve to biomed-
ical prevention trials and 4 FGs and 7 IDIs with participants who have par-
ticipated in biomedical prevention trials. In addition, we included 8
interviews with healthcare providers. The interviews and focus groups
were conducted in Xhosa and transcribed and translated into English. We
followed a framework analysis approach as we analyzed the transcripts
using Nvivo 10.
Results: Overall, participants projected a willingness to use the products in
instances where condom use was inconsistent or non-existent, in cases of
rape, and, in situations of blood contact. Similarly, participants imagined
that sexual relationships amongst discordant couples were now a possibil-
ity. Data also showed that while acceptability and willingness to use these
products were positively influenced by participant’s knowledge and aware-
ness of the products, their conceptualization of product dosing regimens
and the varying levels of efficacy produced inconsistent results. Finally, ac-
ceptability and willingness to use the products were negatively affected by
people’s prevailing socio-economic circumstances as well as their percep-
tion of their cultural expectations defined within a traditional religious
framework.
Conclusion: While biomedical HIV interventions are important, the role of
the social context on the acceptability and possible use of these products
must be considered in the implementation phase.Theme 2: HIV Immunology and Genetics – ImGen
O6
HIV-susceptible target cells in foreskins after voluntary medical
male circumcision in South Africa
Rushil Harryparsad1, Abraham J. Olivier1, Heather B. Jaspan1, Douglas
Wilson2, Janan Dietrich3, Neil Martinson3, Hillary Mukudu3, Nonhlanhla
Mkhize4, Lynn Morris4, Gianguido Cianci5, Minh Dinh5, Thomas Hope5,
Jo-Ann S. Passmore1,6, Clive M. Gray1,6
1Institute of Infectious Diseases and Molecular Medicine, University of
Cape Town, Cape Town, South Africa; 2Department of Medicine,
Edendale Hospital, KwaZulu Natal, South Africa; 3Perinatal HIV Research
Unit, Soweto, South Africa; 4National Institute for Communicable
Diseases, Sandringham, South Africa; 5Division of Infectious Diseases,
Department of Medicine, Northwestern University Feinberg School of
Medicine, Chicago, Illinois, USA; 6National Health Laboratory Services,
Cape Town, South Africa
Correspondence: Rushil Harryparsad (HRRRUS001@myuct.ac.za) –
Institute of Infectious Diseases and Molecular Medicine, University of
Cape Town, Cape Town, South Africa
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Background: Medical Male Circumcision (MMC) reduces the risk of HIV
acquisition by up to 60 %, confirmed in a number of large clinical trials
throughout Africa. MMC has also been shown to reduce the prevalence
of other sexually transmitted infections (STIs), which in turn may impact
HIV acquisition. We hypothesized that the underlying mechanisms for
this protection may be removal of potential target cells for HIV infection
and altered levels of keratinisation in men after MMC.
Methods: In a longitudinal study involving 2 clinical sites and 150 partic-
ipants within South Africa, we investigated CD4+ T cell frequencies by
immunofluorescent imaging in a subset of 10 HIV negative individuals
(14 – 24 years) undergoing elective MMC at Edendale Hospital in Kwa-Zulu
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compared the levels of keratinisation between the inner and outer foreskin
and assessed the impact of STIs (C. trachomatis, N. gonorrhoea, M. genita-
lium, T. vaginalis, HSV-1 & 2) on HIV target cell density in foreskin tissues.
Tanner staging and testosterone levels were measured in all men included
in the study.
Results and Discussions: Preliminary immunofluorescent staining for
CD4, Ki67 and CD207 to identify proliferating immune cells and filag-
grin for keratin layers showed elevated numbers of both CD4+ T and
CD207+ Langerhans cells in the foreskin of men with STIs compared
to those without an STI.
Conclusions: MMC may reduce the risk of HIV infection in this highly
susceptible age group of men by removing the potential CD4+ HIV
target cells present in foreskins of young uncircumcised men in
South Africa. STI-induced inflammation and recruitment of immune
cells to the foreskin, may be elevating the risk of HIV acquisition in
uncircumcised men.
O7
HIV-1 proteins activate innate immune responses via TLR2
heterodimers
Bethany M. Henrick, Xiao-Dan Yao, Kenneth L. Rosenthal, the INFANT
Study Team
McMaster Immunology Research Centre, Michael G. DeGroote Institute
for Infectious Disease Research, Department of Pathology & Molecular
Medicine, McMaster University, Hamilton, Ontario, Canada
Correspondence: Kenneth L. Rosenthal (rosenthl@mcmaster.ca) –
McMaster Immunology Research Centre, Michael G. DeGroote Institute
for Infectious Disease Research, Department of Pathology & Molecular
Medicine, McMaster University, Hamilton, Ontario, Canada
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Background: Chronic immune activation is a fundamental driver of HIV-
1 infection, replication and pathogenesis. Currently, HIV-induced im-
mune activation is believed to be primarily driven by translocation of
bacterial products from the HIV-infected gut into the systemic circula-
tion. However, our understanding of HIV-induced innate immune activa-
tion remains incomplete. Here, we hypothesized that HIV-1 structural
proteins, which persist in infected tissues, may serve as pathogen-
associated molecular patterns (PAMPs) that drive immune activation.-
Methods: These studies made use of TZMbl cells stably transformed to
express Toll-like receptor 2 (TLR2)and primary human T cells.
Results and Discussions: Our results demonstrate that significantly
increased HIV-1 integration occurred in cells expressing TLR2 com-
pared to cells lacking TLR2. Mechanistically, this appeared to be due
to a TLR2-mediated increase in CCR5 expression. Importantly, HIV-1
structural proteins p17, gp41 and p24 were shown to act as viral
PAMPs and were recognized by TLR2 and its heterodimers leading to
significantly increased immune activation via NFkB signaling. Using
co-immunoprecipitation and a cell membrane dot blot method, we
demonstrated direct protein interactions between p17, p24 and
gp41 with TLR2, while only p17 and gp41 bound to TLR1. TLR2/1
heterodimer recognized HIV-1 p17 and gp41 leading to immune acti-
vation, while p24 signaled through TLR2/6. These results were con-
firmed using TLR2/1 siRNA knockdown assays which ablated p17 and
gp41-induced cytokine production and through studies of HEK293
cells expressing selected TLRs. Interestingly, in the absence of TLR6,
p24 bound to TLR2 and blocked signaling by p17 and gp41. Thus,
providing a novel mechanism by which HIV may manipulate innate
sensing.
Conclusions: Our results show for the first time that HIV structural
proteins can serve as PAMPs that activate innate responses via
TLR2 and its heterodimers. These findings have important implica-
tions for our fundamental understanding of innate immune activai-
ton by HIV and also may provide insight into the design of novel
HIV vaccines since HIV proteins that serve as PAMPs have auto-
adjuvant activity.O8
Characterization of an innate factor in human milk and
mechanisms of action against HIV-1
Bethany M. Henrick1, Xiao-Dan Yao1, Anna G. Drannik1, Alash’le Abimiku2,
Kenneth L. Rosenthal1, the INFANT Study Team
1McMaster Immunology Research Centre, Michael G. DeGroote Institute
for Infectious Disease Research, Department of Pathology & Molecular
Medicine, McMaster University, Hamilton, Ontario, Canada; 2Institute of
Human Virology, University of Maryland School of Medicine, Baltimore,
Maryland, USA
Correspondence: Kenneth L. Rosenthal (rosenthl@mcmaster.ca) –
McMaster Immunology Research Centre, Michael G. DeGroote Institute
for Infectious Disease Research, Department of Pathology & Molecular
Medicine, McMaster University, Hamilton, Ontario, Canada
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Background: Previously we demonstrated that immunodepletion of sol-
uble Toll-like receptor 2 (sTLR2) from human breast milk significantly in-
creased HIV infection in vitro. The objectives of this study were to
characterize sTLR2 levels in human milk from HIV-infected and unin-
fected women and identify its mechanisms of action against HIV-1.
Methods: This study was approved by the McMaster Research Ethics
Board and the University of Maryland, Baltimore and Plateau State
Specialist Hospital Nigeria Institutional Review Boards. All participants
provided voluntary written informed consent. Historic breast milk
samples from Nigeria included HIV-infected (n = 40) and uninfected
(n = 15) samples, and HIV-uninfected breast milk samples from
Hamilton, Ontario (n = 13) were blindly tested. ELISA assays were
used to measure TLR2 and HIV-1 p24.
Results and Discussions: Breast milk from HIV-infected women had
significantly elevated levels of sTLR2 compared to uninfected breast
milk. sTLR2 levels correlated with HIV-1 p24 and IL-15 in milk, thus
suggesting a local innate compensatory response in the HIV-infected
breast. Next we demonstrated that mammary epithelial cells and
macrophages produced significantly increased levels of sTLR2 follow-
ing exposure to HIV-1 proteins, p17, p24 and gp41 or the TLR2 lig-
and, Pam3CSK4. Further, sTLR2 directly interacted with p17, p24 and
gp41 as shown by co-immunoprecipitation. Importantly, sTLR2 sig-
nificantly inhibited cell-free R5 HIV-1 infection, inflammation and
NFκB activation. Mechanistically, binding of sTLR2 to HIV-1 proteins
inhibited a TLR2-dependent increase in CCR5 expression, thus result-
ing in significantly reduced HIV-1 infection.
Conclusions: Our findings showed that sTLR2 significantly inhibited
HIV-induced NFκB activation and inflammation in a dose-dependent
manner; sTLR2 bound directly to HIV structural proteins; and sTLR2
inhibited TLR2-dependent, HIV-induced increases in CCR5 co-
receptor expression. Together, these likely contribute to significant
decreases in HIV MTCT.
O9
Secretor status and susceptibility to HIV infections among female
sex workers in Nairobi, Kenya
Nadia Chanzu, Walter Mwanda, Julius Oyugi, Omu Anzala
KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
Correspondence: Nadia Chanzu (nadiachanzu@gmail.com) – KAVI
Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
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Background: Blood group antigens are expressed on red blood cells
however; these antigens can also be expressed on some other cells par-
ticularly on the surface of epithelial cells and may be found in mucosal
secretions. The gene known to determine the secretion of these blood
group antigens is the Secretor Fucosyltransferase 2 (FUT2) gene. In many
human populations 80 % secrete ABO antigens (termed secretors) while
20 % do not (termed non-secretors). Furthermore, there are disease condi-
tions that are associated with secretor status. It is against this background
that this study was proposed: To investigate associations between mucosal
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gene polymorphisms and susceptibility to HIV infection among female sex
workers in Nairobi, Kenya.
Methods: This study recruited 280 female sex workers from the well-
established Pumwani Majengo cohort aged 18 to 65 years of age. Blood
typing was determined using standard serological techniques using mono-
clonal antibodies to the ABH, Rhesus (D) and Duffy (Fya, Fyb) blood group
antigens. Secretor phenotyping was determined using lectins specific to
blood group H antigen in both salivary and female genital tract samples.
This was correlated to the HIV sero-status.
Results and Discussions: Saliva testing showed that 212 (76 %) study cases
were secretors and 68 (24 %) non-secretors. Based on HIV screening, 92
(32.9 %) were HIV-1 infected and 188 (67.1 %) HIV-1 uninfected. There was
a correlation between HIV infections and secretor phenotypes. The propor-
tion of secretors was significantly higher among women with HIV infection
(77/92 = 83.7 %) in comparison to HIV un-infected women (135/188 =
71.8 %) (p = 0.029). Furthermore, the incidence of HIV infection was signifi-
cantly higher among blood group A secretors (p = 0.028) in comparison to
O secretors, but not B and AB.
Conclusions: These findings suggest the non-secretor phenotype may
confer a certain degree of protection against HIV infection, as there
were higher HIV infection incidence rates among ABH secretors.
O10
Natural Killer cell recall responsiveness to Gag-HIV-1 peptides of
HIV-1 exposed but uninfected subjects are associated with
peripheral CXCR6+ NK cell subsets
Moustapha Mbow1, Sabelle Jallow2, Moussa Thiam1, Alberta Davis2,
Assane Diouf3, Cheikh T. Ndour3, Moussa Seydi3, Tandakha N. Dieye1,
Souleymane Mboup1, Martin Goodier4, Eleanor Rilley4, Assan Jaye1,2
1Laboratory of Bacteriology and Virology of Aristide Le Dantec University
Hospital, Dakar, Senegal; 2Medical Research Council (MRC) Unit,
Serrekunda, The Gambia; 3Clinic of Infectious Disease of Fann University
Hospital, Dakar, Senegal; 4Department of Immunology and Infection,
London School of Hygiene & Tropical Medicine, London, UK
Correspondence: Moustapha Mbow (moustaphazero@yahoo.fr) –
Laboratory of Bacteriology and Virology of Aristide Le Dantec University
Hospital, Dakar, Senegal
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Background: Despite that NK cells are traditionally defined as innate im-
mune cells, increasing evidences suggest that NK cells contribute to
antigen-specific secondary immune responses upon both specific and
non-specific activation. Although it has been reported in models of virus
infections that secondary virus-specific NK cell responses are restricted
to CXCR6+ and/or Thy1+ NK cell subsets, the function and phenotype of
human NK cells to protect against HIV infection or limit HIV transmission
remains unclear. Here we investigated effector responses and putative
“memory” phenotype of NK cell in HIV-1 infected adults and their HIV-
exposed but uninfected partners as well as HIV-negative controls.
Methodology: We selected 48 HIV-1 positive individuals and their HIV-
negative partners from a sero-discordant cohort in Dakar, Senegal and
28 HIV-sero-negative subjects as controls. PBMCs were stimulated for
18 h with whole HIV-1 clade A peptide pools of Reg (Tat, Rev, Vif, Vpu,
and Vpr) and Gag, and Env 15-mers overlapping by 10 amino acids. We
used multiparametric flow cytometry to analyze NK cells including the
functional markers CD107a and IFN-γ and CXCR6. Differences between
groups were assessed using the nonparametric Krushal-Wallis H and
Mann-Whitney U tests and correlations performed using the Spearman
Rho test.
Results: The proportion of NK cells producing IFN-γ in response to Gag
peptides were significantly higher in exposed-uninfected partners (2.2 %
[IQR:1.4-3.1]) compared to their HIV-1 positive partners (1.5 % [IQR:1.1-
2.0], p = 0.013) and controls (0.8 % [IQR:0.7-1.0], p < 0.001). Moreover,
CD107a-expresssing NK cells in response to Gag peptides were higher
among HIV-exposed but uninfected partners (3.4 % [IQR:2.8-4.3]) than
among controls (1.9 % [IQR:1.3-2.7], p < 0.001). Interestingly, the CXCR6
mean fluorescence intensity of NK cells was positively correlated withIFN-g-producing NK cells in HIV-exposed infected (r = 0.49 p = 0.001) and
uninfected (r = 0.47; p = 0.05) subjects but this was not the case in con-
trols CD107a (r = 0.05; p = 0.98).
Conclusion: These data suggest that exposure of NK cells to HIV anti-
gens may prime specific recall functional response that would be im-
portant for protection against HIV. Despite evidences that antigen-
specific IL-2 CD4+ T cells might be important for NK cell function, such
responses might be mediated by the CXCR6+ (putative “memory”)
phenotype.
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Background: Highly HIV-1-exposed seronegative (HESN) cohorts of fe-
male commercial sex workers (CSWs) were first identified in Kenya.
Given that natural resistance to infection is primarily mediated by innate
immune mechanisms as well as many studies suggesting that HESN
women have novel immune responses in the genital mucosa associated
with protection, the main objective of this study was to determine
whether expression and function of innate sensing and signaling path-
ways were altered locally in the genital mucosa of HIV-1 resistant
women in a well-characterized cohort of Kenyan CSWs.
Methods: This study was guided by the Helsinki Declaration on ethical
principles for medical research involving human subjects. All studies
were approved by the University of Nairobi/Kenyatta National Hospital
Ethical Review Board and University of Manitoba Health Research Ethics
Board. All participants provided written informed consent for sample
collection and analysis. Participants from the Pumwani CSWs cohort
were enrolled in 2009 for this study and divided into three groups:
HESN, HIV-negative (HIV-N), and HIV-positive (HIV-P), based on their
HIV seroconversion status at the time of collection. Mucosal samples
collected included cervicovaginal lavage (CVL), cervical mononuclear
cells (CMCs) and cervical epithelial cells (CECs). RNA was extracted
from CMC and CECs and quantitative reverse transcriptase PCR (qRT-
PCR) to quantitate gene expression. Freshly isolated CMCs were stimu-
lated to assess responses to pathogen-associated molecular patterns
(PAMPs) in vitro.
Results and Discussions: Our results demonstrated that selected in-
nate pattern recognition receptors (PRRs) were significantly reduced in
expression in CMCs from HESN compared to HIV-N and HIV-P groups.
Although baseline levels of secreted cytokines were reduced in CMCs
of HESN, they were highly stimulated following exposure to ssRNA40
in vitro. Importantly, CECs from HESN also expressed reduced levels of
PRRs, but Toll-like receptor 3 (TLR3) and TLR7, as well as NFκB and AP-
1 were highly expressed and activated. Lastly, inflammatory cytokines
IL-1β, IL-8, and RANTES were detected at lower levels in the CVL of
HESN compared to HIV-N and HIV-P groups.
Conclusions: Our study reveals a local microenvironment of HIV re-
sistance in the genital mucosa consisting of a finely controlled bal-
ance of basal immune quiescence with a focused and potent innate
anti-viral response that may be critical to resistance of sexual trans-
mission of HIV-1.
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Background: In Benin, female sex workers (FSWs) are at the heart of the
HIV epidemic. Within a combination prevention framework, we are cur-
rently carrying out a demonstration project on treatment as prevention
(TasP) among HIV-positive FSWs (they receive a first-line ART regimen as
per the Benin guidelines) and pre-exposure prophylaxis (PrEP) with Tru-
vada® among those HIV-negative. The study is conducted at Dispensaire
IST, a STI clinic dedicated to FSWs in Cotonou. It aims to assess the feasi-
bility and usefulness of integrating TasP and PrEP to the combination
prevention package offered to FSWs in Benin.
Methods: After a community preparedness phase and the development
of a specific education program on adherence, we are currently recruit-
ing 100 HIV-infected FSWs for TasP and 250 HIV-negative FSWs for PrEP.
The recruitment period will last for one year, followed by an additional
one year of follow-up. The actual recruitment visit is preceded by a
screening visit two weeks earlier in order to determine the HIV status
and assess other eligibility criteria. Through Day 14 and quarterly follow-
up visits, we closely monitor treatment adherence and changes in sexual
behaviour, using various tools including biological markers. We report
on the first two months of the clinical phase of the study.
Results and Discussions: From 18th September to 17th November 2014,
we screened 84 FSWs and out of them, 41 were recruited in the PreP
arm and 17 in the TasP arm, with recruitment rates among eligible FSWs
estimated at 93 % and 100 %, respectively. To 17th November, the reten-
tion rate at Day 14 was 100 %. The most common side effects reported
in the PrEP arm were restlessness, polyphagy and headache; all were
minor and resolved within 2 weeks following initiation of treatment. It is
of interest to note that the cumulative incidence of pregnancy was 7 %
between the screening visit and the Day 14 follow-up visit.
Conclusions: The recruitment rate is on target and FSWs show a great
interest in the study. Its successful completion will allow a better delin-
eation of the role of TasP and PrEP in HIV prevention packages aimed at
FSWs in the African context.
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HIV/AIDS; 3.5 million people are still living with HIV/AIDS by the end of
2013 with new HIV infections annually. In the last 5 years, a series of in-
novative prevention tools have been added to the arsenal to combat
the epidemic with some success. However an effective HIV vaccine is
still crucial to ending the epidemic. HIV exposed Sero-Negative (HESN)
individuals have been identified as an important group for HIV preven-
tion studies. This study builds the capacity for successfully conducting
future clinical trials in a resource limited setting as ours.
Methods: A total of 536 heterosexual HESN adults were enrolled by De-
cember 2012 into a cohort in Jos, Nigeria. Study enrollees and their HIV
positive partners were screened, confirmed HIV sero-discordant and en-
rolled. At follow up visits behavioral data were collected and medical ex-
aminations and lab testing performed. Research team was trained to
assess eligibility based on laboratory test results. Trackers were able to
contact volunteers to remind them about their visits and make sure of
their willingness to continue in the study.
Results and Discussions: Out of 536 HESN volunteers 256(47.9 %) were
female and 278 (52.1 %) male with a mean age of 37 ± 9 years. There
were a total of 98 (18.0 %) HESN terminated from the study, after a fol-
low up period of 3 years and 10 months. We recorded deaths of HESN
from natural causes (5) and that of their HIV positive partners from AIDS
related illnesses (22). Testing HIV positive partners showed that 1/3 had
detectable viral loads with ranges of 20-2,186,199 copies/ml. Baseline
male condom use showed that couples with F + M- were less likely
to use condoms consistently. HIV incidence is 3.2 % per 100 person
months.
Conclusions: One of our aims was to build capacity of a research
site to conduct clinical trials and be able to enroll and retain volun-
teers in a study. Our team successfully collected data and retained a
cohort of HESN. Overall, male condom use in the cohort remained
low despite regular. Viral load results also indicate that HESN are still
at risk of getting infected.
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Background: KAVI Institute of Clinical Research (KAVI-ICR) in collabor-
ation with the Universities of Manitoba and Toronto received a grant
from the Global Health Research Initiative (GHRI) through IDRC to con-
duct capacity building to establish KAVI-ICR as a centre of excellence for
the training of healthcare professionals with the skills required for the
conduct of clinical trials in the region.
Methods: Using networks of research collaborators/Institutions that
KAVI-ICR has established over years, Good Clinical Practice training (GCP)
needs among the clinical trial teams were identified. The research insti-
tutions approached were only expected to cover the cost of the venue
and lunches for the training period. Using a KAVI-ICR experiential GCP
approach developed over a long standing of Clinical research experi-
ence, training modules were developed which included a Good Clinical
laboratory Practice( GCLP) and Good Participatory Practice( GPP) compo-
nent. In order to address the issue sustainability of the training program
beyond the duration of the IDRC grant, members of staff from within
the site were identified and mentored to continue GCP trainings within
their clinical sites and the region.
Results and Discussions: Between 2010 and 2014 a total of 418 clinical
site staffs and the numbers increased with increased awareness of the
training opportunity. The trained staff included physicians, Nurses, com-
munity health workers Laboratory technologists, IT/Data Clerks and
Managers, Research assistants/secretaries/administrators, Principal and
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working in Clinical sites from Kenya, Uganda, Tanzania, Rwanda and
Botswana.
Conclusions: The face to face GCP training was highly appreciated
based on the feedback received from the training evaluation.
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Background: Recent educational literature stresses the importance of
techniques to support active learning. Participants in training offered to
HIV researchers and planners come with experience and need to inte-
grate new learning into their professional settings.
Methods: A three week intensive face-to-face training course in
Botswana for 22 HIV researchers and planners from 12 SADC countries
covered foundations of epidemiology, basic analysis of health data,
introduction to research, and reviews of published articles. We used an-
droid tablet devices and the open access Socrative software to support
active learning. Socrative allows immediate responses to sets of ques-
tions – pre-designed or “off the cuff” – which can be teacher- or
student-timed, and with different options for displaying the responses.
Single answer, multiple response and narrative responses are possible.
The participants accessed Socrative via a free app. Prior to teaching
about different concepts, the participants used the tablets to respond to
questions to indicate their existing understanding. During the sessions,
they tested their understanding by responding to questions on the tab-
lets that related the concepts to potential scenarios they might encoun-
ter in their work. We also used the tablets and software to seek the
views of the participants about the training and its relevance to them.
Results: All 22 participants actively used the Socrative software, al-
though they had never used such software before. Results from the ini-
tial question sets helped teachers to tailor their sessions according to
the needs of the participants. The Socrative exercises largely replaced
paper exercises, and were well-received. Most (18) participants found
using Socrative a good experience and none found it bad. All consid-
ered it had helped their learning and 18 agreed it had helped them re-
flect on their own experience and knowledge. Positive aspects
highlighted by participants included instant feedback, the “one to one”
aspect, exercises in applying the concepts, and being able to test one’s
learning several times.
Conclusions: The active learning approach worked well with the partici-
pants in the training and was effectively supported by the educational
technology we used. We intend to build on this experience for future
face to face and distance learning for similar groups.
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Background: The provision of clinical care requires adequate access to
quality laboratory support. The majority of significant illnesses require la-
boratory confirmation of the diagnosis, and laboratory monitoring of the
patient after the diagnosis has been made. The capacity to plan andimplement an effective laboratory system that meets the requirements
of quality management systems depends on the availability of highly-
trained and motivated personnel that are not only technically compe-
tent, but also possess strong leadership and managerial skills. Capacity
strengthening is not only acquisition of modern equipment and re-
agents but also sustained commitment to training and quality.
Methods: KAVI-ICR was awarded a four-year grant by the Global Health
Research Initiative of Canada (GHRI-Canada) to establish a center of ex-
cellence for the training of healthcare professionals in the conduct of
clinical trials. KAVI-ICR developed, piloted and delivered a course on
Good Clinical Laboratory Practice (GCLP) and trained laboratory staff
from four countries in the East African region. The modules were
grouped according to the 12 Quality System Essentials, together with
their respective learning objectives. The laboratory staffs trained from
the four countries were from research, public health and private la-
boratories.
Results and Discussions: A total of 886 laboratory staff from Kenya,
Uganda, Tanzania and Rwanda were trained were trained from 2010 to
2014. 35 % were trained in Kenya, 30 % in Tanzania, 20 % in Uganda
and 15 % in Rwanda. In addition Laboratory management staff in each
of trained laboratories were trained and encouraged to implement a
quality management system. This included development and imple-
mentation of quality and technical manuals, standard operating proce-
dures (SOPs), and a document control system.
Conclusions: The ultimate goal of the training program was to im-
prove the quality of laboratory services, achieve compliance with GCLP
standards, gain ISO 15189 accreditation, and facilitate better clinical
care and collaborative research. It was clear that laboratory staff were
motivated to improve the quality of their testing and services when
working toward a concrete endpoint such accreditation. Enhancing la-
boratory capacity through training is essential for generating reliable
and accurate data from clinical research, especially in resource-constrained
settings.
Theme 4: HIV Treatment and Clinical Intervention –
TxCln
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Background: Rilpivirine (RPV) and Etravirine (ETR) are the recently ap-
proved second-generation non-nucleoside reverse transcriptase inhibi-
tors (NNRTI) for HIV treatment. There is a substantial cross-resistance HIV
mutation profile between first-generation NNRTI and the second-
generation drugs. Prevalence of resistance-associated mutations (RAM)
to RPV and ETR has not been documented in Botswana.
Methods: A total of 274 HIV-1 pol sequences from participants failing
Nevirapine or Efavirenz-containing regimens were analyzed. The selected
genotypes, in the form of FASTA files were uploaded into the Stanford Uni-
versity HIV drug resistance database for HIV-1 genotype resistance inter-
pretation. Forty- two sequences were from an adult antiretroviral therapy
(ART) study and 232 from a prevention of mother-to-child transmission
(PMTCT) study in Botswana.
Results and Discussions: Prevalence of RPV and ETR RAM in the adult ART
study (n = 42) were: V90I (16.7 %), A98G (7.1 %), K101E (26.2 %), V108I
(7.1 %), E138A (23.8 %), E138K (2.4 %), E138G (4.8 %), V179D (4.8 %), V179I
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The most prevalent mutation was Y181C, which causes intermediate resist-
ance to RPV and ETR. The PMTCT cohort (n = 232) most prevalent muta-
tions were Y181C and E138A (both 8.2 %). The E138A mutation reduces
HIV-1's susceptibility to both drugs. The K101E mutation prevalence was
26.2 % and 6.5 % for adult ART and PMTCT studies, respectively. This muta-
tion is linked with low-level resistance to RPV and ETR, and also affects
NNTRIs. In total 108/274 (39.4 %) of patients harbored RPV and ETR RAMs.
A total of 42.9 % of patients in the adult ART study had 3 or more NNRTI
mutations at virologic failure.
Conclusions: Although RPV and ETR are not yet used in Botswana, HIV-
1 mutations conferring resistance to them have been identified at
39.4 % in studied participants. The levels of NNRTI cross-resistance in-
creases with the increase in number of mutations a patient has, and
this was high in the adult ART study. These findings are crucial in pa-
tients displaying such profiles in receipt of these second-generation
drugs in the future hence calls for genotyping of patients with prior
nevirapine or efavirenz exposure before prescription of RPV or ETR-
containing cART.
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Background: This paper examines the cascade of HIV testing, support
and treatment services in Uganda under the TASO HBHCT program and
compares the patterns among adolescents aged 10-19 years with those
of adults aged 20 years and above.
Methodology: Data included individuals who were counselled and
tested for HIV at their homes through the TASO HBHCT program.
Analysis entailed simple frequencies to determine the proportions of
adolescents and adults that: (i) tested positive among those who re-
ceived HBHCT from 2005 to 2011; (ii) were enrolled in care and sup-
port programs at TASO centres among those who tested positive
during HBHCT; (iii) were determined to be eligible for ART among
those who were enrolled in care and support programs at TASO
centres; and (iv) were initiated on ART among those who were de-
termined to be eligible.
Results: Between 2005 and 2011, TASO tested a total of 55,228 cli-
ents aged 10 years and above through the HBHCT program; 40 %
were adolescents aged 10-19 years. The proportion of adolescents
who tested positive under the program was consistently lower than
that of adults across the years (between 2 % to 5 % compared to
between 10 % and 14 % among adults). The proportion of HIV-
positive adolescents that were enrolled in TASO centres more than
tripled from 9 % in 2005 to 32 % in 2006 and steadily increased to
41 % in 2008. By contrast, the proportion of HIV-positive adults that
were enrolled in TASO centres increased from 21 % in 2005 to 31 %
in 2006 before levelling off at 33 % in 2007.The proportion of ado-
lescents who were found to be eligible for ART more than doubled
from 15 % in 2006 to 40 % in 2011 while the proportion of eligible
adults increased from 16 % in 2006 to 36 % in 2007 but fluctuated
between 30 % and 35 % thereafter. Among those who were eligible
for ART between 2005 and 2011, 89 % of adolescents and 93 % of
adults were initiated on ART at TASO.
Conclusions: The HBHCT program contributed to improved uptake
of HIV services among adolescents aged 10-19 years who would
otherwise not have accessed the services at all or in time.O19
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Background: HIV infected and tuberculosis (TB) patients have difficulties
in reaching adequate levels of adherence (>95 %) to treatment. Many
factors may influence adherence. One way to intervene is real time
medication monitoring (RTMM). We conducted a pilot study on the use
of RTMM in a resource-limited setting where factors such as network
connectivity and electrical power stability play role.
Methods: We enrolled five HIV infected and five TB patients from
Kilimanjaro region, Tanzania. They took their medication from an RTMM
device for three months. The device sent a signal through the mobile
network when it was opened (so-called medication event) to a database.
In the database, we recorded the usual time of intake. When the device
was not opened on time, patients received a reminder SMS. After three
months, we interviewed patients on acceptability of RTMM and carried
out quantitative and qualitative analyses of the data.
Results and Discussions: Six patients (60 %) reached adequate adher-
ence, two HIV infected (40 %) and four TB patients (80 %). In total, there
should have been 1104 medication events. Nine-hundred-twenty-two
events (84 %) were on time. In 455 events (41 %), a reminder was sent,
but this was not correct in 170 events (37 %). This means that the net-
work was not stable enough to send the signal on time. The median
number of battery charging was one time. Qualitative results showed
that nine patients found the device helpful. All mentioned that it helped
to remind them; nine mentioned it keeps medication safe and seven
found it easy to carry the device. However, six patients reported that the
size was too big. The SMS was considered fine by nine patients, but five
patients recommended to also get an SMS before usual time of intake.
Five patients experienced the network problem by receiving a reminder
while they had already taken their medication. One patient suggested
solar power to be provided to avoid charging problems.
Conclusions: Based on the analyses, the device is considered useful in
the resource-limited setting Kilimanjaro. In this setting, optimisation of
the device should consider issues related to network connectivity, power
supply, and the size of the device.
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Background: Low CD4 counts and high HIV viral load are known predic-
tors of HIV transmission and mortality in HIV positive individuals. Since
the introduction of ART in many resource limited countries like Nigeria,
the number of deaths attributed to HIV infection have drastically re-
duced, however deaths that should have been averted due to the wide
spread treatment programs are still occurring. We explored the reasons
for partner deaths in a cohort of sero-discordant couples followed for
2 years.
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tive partners and followed up for 2 years in Jos, Nigeria. Data on
partner deaths were collected through a follow up period from No-
vember 2011 to August 2014. Death of partners was a criterion for
couple termination and therefore exiting the study.
Results and Discussion: Among 536 enrollees and their HIV positive
partners, we recorded a total of 23 deaths (4 %). Out of 23 deaths 10
(43.5 %) were females and 13 (56.5 %) were male with a mean age
of 37 years old. Eleven (48 %) deceased HIV positive partners re-
ported never using male condoms (OR 1.4). The average CD4 count
and viral loads of the deceased HIV+ partners were 235 cells/μl and
257,445 copies/ml respectively despite being on ARTs for an average
of 5 years. A majority of recorded deaths were due to AIDS related
complications underscoring the need for better adherence to drugs.
Conclusions: Our study shows that sero-discordant couples in Nigeria
and possibly in other African countries still experience loss of their
HIV positive partners despite treatment programs. Our data indicates
that more efforts need to be directed towards support and adher-
ence counselling for partners in care and treatment programs in
addition to drug resistance monitoring. Such efforts would also im-
prove retention for HIV prevention studies including HIV vaccine tri-
als. We found low use of condoms by couples due to reasons like
procreation, religious belief and male partner refusal to use male
condoms.
Theme 5: HIV Vaccine Research and Vaccine Trials –
Vac
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Background: Therapeutic HIV vaccine is being pursued as part of a func-
tional cure for HIV/AIDS. We designed a universal peptide vaccine
(AFO18) matching the populations and HIV-1 strains in two distant geo-
graphic regions, Denmark, and Guinea-Bissau, West Africa. The vaccine
represents 15 subdominant CTL epitopes restricted to 5 common HLA
supertypes + 3 Th epitopes in the adjuvant CAF01.
Methods: Two single-blinded phase-I therapeutic HIV-1 vaccine trials are
referred to, one in Denmark and one in Guinea-Bissau. Capacity to con-
duct clinical HIV vaccine trials in West Africa was built with WAPHIR dur-
ing the study. Treatment-naïve HIV-1-infected individuals with high CD4
counts where immunized i.m. (week 0, 2, 4, 8) with AFO18. Placebo
groups received saline.
Results and Discussions: In Denmark 11 individuals (10 vaccinees + 1
placebo), and in Guinea-Bissau 18 individuals (15 vaccinees + 3 placebo)
completed all vaccinations and 6 months of follow-up. The vaccine was
safe and well tolerated. No overall or sustained changes in viral-load or
CD4+ T cell counts occurred; however, new T cell responses specific for
one or more vaccine epitopes were induced (IC-FACS and/or ELISpot).
Surprisingly, the immunogenicity of the T-cell vaccine as well as the pre-
existing T-cell immunity to HIV-1 seem to be lower in this West African
HIV-1 positive population as compared to the Danish population.
Conclusions: We show that it is possible to generate new T cell responses
in treatment-naïve HIV-1-infected individuals using peptides in adjuvant
and thereby redirect immunity to selected subdominant conserved CTL
epitopes. We demonstrate that it is possible to design a broad vaccine that
is immunogenic in two very different geographic regions. This broad T cellvaccine is an important proof-of-concept for further development prefer-
entially using stronger adjuvant (CAF09) and during (early started) ART to
minimize viral-load and restore immune function.
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Background: Nigeria has the second highest burden of HIV infection fol-
lowing South Africa. The presence of subtype G virus in Nigeria offers a
unique opportunity to examine the efficacy of an appropriate vaccine
on a well characterized cohort of HIV exposed sero-negative (HESN) per-
sons. In preparation for a future HIV vaccine trial, we document here the
willingness of HESN persons in a discordant relationship residing in Jos
Nigeria to participate in such a trial.
Methods: We developed a prospective cohort study in the format of
mock clinical trial and followed up participants for 2 years. We provided
prerequisite risk reduction counseling and HIV testing during the 10
follow-up visits over the 2 years follow-up and administered semi struc-
tured interviewer based questionnaire to assess willingness to partici-
pate in HIV vaccine trials among others. We analyzed correlated
proportions at visits 1 and 10 using Mcnemars exact test.
Results and Discussions: We screened 660 persons and 534 were en-
rolled. We had a mean age 37 ± 9 years (19-65 years) and 48 % (256/
534) being female HESN respondents. At enrollment, only about 14 %
(72/534) had heard about HIV vaccine and this became 100 % at visit 10
(p value < 0.001). Also at enrollment, 99.2 % (530/534) were willing to
participate in HIV vaccine trial and 97.4 % (520/534) would allow some-
one under their care to participate in such a trial. These became 100 %
also as the study progressed to visit 10 (p value = 1.0 and 0.036 respect-
ively).
Conclusions: HESN partners in a discordant relationship in Nigeria are
willingness to participate in HIV vaccine trial. Thus funding a candidate
vaccine among this group is crucial in sustaining this willingness.
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Background: The goal of clinical research is to develop knowledge and
advance medical treatments to improve human health outcomes. It in-
volves recruitment of volunteers who must not only be willing to be en-
rolled and retained to participate in the studies to completion but also
meet the eligibility criteria. At KAVI-Institute of Clinical Research, Kenya
data from recruitment sites reveal that some eligible volunteers fail to
turn up for enrollment. Studies have suggested that understanding par-
ticipants’ perceptions and research experiences not only provides valu-
able measure of their ethical treatment but is critical for enhancing their
overall research experiences and outcomes. In response, a study on vol-
unteers’ perceptions and experiences of clinical research participation in
Kenya was conducted among KAVI-ICR volunteers in 2014. This study ex-
plored volunteers’ perceptions and experiences at all stages of participa-
tion and potential impact on motivation and decision making.
Methods: A mixed method approach was applied. A survey questionnaire
was administered to 166 volunteers from 6 selected KAVI-ICR studies. Out
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and 4 narratives. In addition 6 peer educators, 8 trial staff were inter-
viewed as key informants. Quantitative data was coded and analyzed
using SPPS. Qualitative data was transcribed verbatim, thematic
themes identified for code tree development, coded and entered into
Atlas ti for analysis.
Results and Discussions: In this paper we share qualitative findings on
volunteers’ perceptions of screening for eligibility in clinical research
participation. Volunteers expressed mixed reactions about the screen-
ing process and outcomes. Overall the medical examination and being
confirmed to be in good health was most appreciated as most volun-
teers had for the first time received free and comprehensive medical
check-ups. They however, volunteers indicated having had fears about
test outcomes for HIV and serious ailments prior to screening. Add-
itionally concerns about blood and mucosal samples were raised and
these varied across gender and sexual orientation.
Conclusions: Findings suggest that beyond willingness to participate,
understanding and consenting, gender, sexual orientation and study
type shapes volunteers’ perceptions and experiences with study re-
quirements, procedures and processes; that ultimately influence motiv-
ation to participate in clinical research.
O24
Gut microbiome, HIV-exposure, and vaccine responses in South
African infants
Katie Viljoen, Jerome Wendoh, Elvis Kidzeru, Ulas Karaoz, Eoin Brodie,
Gerrit Botha, Nicola Mulder, Clive Gray, William Cameron, Alain Stintzi,
Heather Jaspan, for the INFANT study team
Division of Immunology, Institute of Infectious Disease and Molecular
Medicine, University of Cape Town, Cape Town, South Africa
Correspondence: Heather Jaspan (hbjaspan@gmail.com) – Division of
Immunology, Institute of Infectious Disease and Molecular Medicine,
University of Cape Town, Cape Town, South Africa
BMC Infectious Diseases 2016, 16(Suppl 2):O24
Background: The gut microbiome is crucial for mucosal and systemic
immune development. In mice, certain bacteria are required for induc-
tion of Treg and Th17 cell development in the gut. Likewise, gut micro-
biota enhance immune responses to influenza vaccination. HIV-infected
women have altered vaginal and gut microbiome, and HIV-exposed
infants (HEU) and their mothers receive antibiotics for PCP prophy-
laxis, therefore HEU may have altered gut microbiota. HEU have in-
creased morbidity and mortality than HIV-unexposed (HU) infants,
and respond poorly to certain infant vaccinations. We hypothesized
that the etiology of this relative immune deficiency is mediated by
gut dysbiosis.
Methods: HEU and HU infants were recruited from informal settle-
ments of Cape Town. Stool DNA was extracted using MoBio PowerFe-
cal DNA kit and 454 or Illumina sequencing was performed. Data was
preprocessed using QIIME and UPARSE and imported into R for fur-
ther analyses using the R package phyloseq. Differential abundance
testing was performed at OTU level using the R metagenomeSeq
package. Whole blood was incubated with BCG and proliferation and
cytokine expression measured using multiparameter flow cytometry.
Results and Discussions: We found substantial differences in bacterial
diversity between HEU and HU infants by Shannon index. Moreover,
at all taxonomic levels, there were differences between the groups
via PCoA analysis. Several OTUs of the phylum Firmicutes were differ-
entially abundant between HIV exposed and HIV-unexposed infants,
three of which were of the genus Veillonella. In HU infants, several
key species were significantly correlated with both proliferative and
cytokine responses to BCG. For example, at 6 weeks of age, signifi-
cantly decreased abundance of Bacteroides spp. and in particular B.
fragilis were present in infants with high CD4 + IL-2, CD8 + ki67+, and
CD8 + IL-17+ responses at week 6.
Conclusions: Gut microbial makeup could explain the immunological
differences between HU and HEU infants. Although the differences
persisted after adjustment for feeding status, future work will focus
entirely on breastfed HEU infants in the INFANT study.O25
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Background: My laboratory is interested in testing the hypothesis that
concentrated HIV epidemics, in which HIVs of limited genetic diversity
are circulating, are valuable populations for HIV vaccine development
and testing. This hypothesis relates to the goals of the Botswana-Canada
AIDS Vaccine Discovery Partnership; however challenges have arisen in
setting up the latter study and sample collection is only now beginning.
Thus, in the interim, my lab has sought to study HIV genetic diversity in
a concentrated epidemic here in Canada; that is, the HIV epidemic in
Saskatchewan.
Methods: Plasma samples collected from patients entering clinics in Sas-
katchewan were sent to the Public Health Agency of Canada (PHAC) for
routine HIV pol sequencing. Residual plasma samples were shipped to
Simon Fraser University, and the same pol region, and also the V3 re-
gion of the HIV envelope gene (env) were sequenced.
Results and Discussions: Analysis by collaborator, Paul Levett (SK Dis-
ease Control Laboratory), of pol sequences from newly diagnosed infec-
tions obtained by PHAC between 2004 and 2012 indicate that HIV is
somewhat diverse, but also shows differential clustering in two urban re-
gions, and with patterns that have been stable over time. Our phylogen-
etic analyses of the HIV env V3 region showed similar characteristics. We
have begun cloning full-length env from plasma samples, and collabora-
tors at University of Saskatchewan are setting up to collect blood from
~250 HIV+ participants over the coming 9 months. We will be testing
the hypothesis that HIV+ individuals who harbor viruses with closely re-
lated envs will produce antibodies that will “cross-neutralize” each
other’s viruses. A positive result would support further testing of these
dominating envs as vaccine candidates.
Conclusions: The impact of the proposed study is two-fold. First, while a
multi-envelope vaccine will not target all circulating strains in Saskatch-
ewan, or those of a comparable concentrated epidemic, it may provide
protection against Saskatchewan’s dominant circulating strains (proving
vaccine efficacy). Second, demonstration of antibody-mediated protec-
tion in humans would finally bring unambiguous positive results to the
HIV-vaccine research effort.Poster presentations
Theme 1: Behavioral and Social approaches to
prevention – BeSo
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Background: In developing an HIV vaccine, the clinical trial context
poses some intrinsic and extrinsic challenges, which need to be taken
into account when evaluating community engagement processes. The
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ation of trial and implementing the highest quality standards in trial
protocol while, at the same time, leaving the community better off. The
extrinsic challenges are dovetailing clinical trial efforts with other HIV
risk reduction strategies, addressing social and contextual issues, such as
poverty, unemployment and education, in communities with individuals
at high risk of HIV infection, as well as respecting human rights and
dealing with ethical dilemmas in the process. These challenges emphasis
the importance of the involvement of the community in HIV vaccine tri-
als (HIVVTs). Communities are, however, complex. Efforts to develop a
safe, efficacious HIV vaccine must be based on collaboration and part-
nerships among all stakeholders involved. The aims of the study are to
describe the context of community participation with regard to HIV vac-
cine trial participation and to evaluate current activities and approaches
to community participation and knowledge dissemination.
Methods: The research is being conducted in two phases. The study
is being conducted at the Masiphumelele HIVVT site and the Men’s
Research division of the Desmond Tutu HIV Foundation (DTHF). The
participants consist of community engagement staff and community
members. Interviews and focus group discussions are being con-
ducted. The interviews and focus group discussions are audio-
recorded and transcribed and the data obtained analysed with the
use of thematic analysis as described by Braun and Clarke (2006).
Results and Discussions: The data are being collected and analysed
at present.
Conclusions: This research aims to contribute to the knowledge on
developing contextually relevant and culturally sensitive community
engagement activities that align with existing processes in two local
communities. This community participation project is funded by
CHVI.
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Background: HIV sero-discordancy is reported as a preventable source of
new infections. The provision and impact of biomedical prevention pro-
grams such as the pre-exposure prophylaxis can be optimized when
high risk HIV exposed sero-negative (HESN) persons are targeted. Toward
this end, a risk scoring tool was developed and published by Kahle
et al (2013) using data from South and East African countries. We
validate this empirical tool using a cohort of HESN residing in Jos,
Nigeria, West Africa.
Methods: The original study enrolled and followed up 500 HESN for
2 years based on define eligibility criteria such as: established HIV
sero-discordance with at least 3 months in the relationship; above
18 years etc. Following ethical approval and informed consent, we
administered standardized questionnaires on risk behavior, medical
history and performed safety lab test. We also obtained medical his-
tory and performed CD4 and viral load test on HIV+ partners of this
cohort. To apply the risk score to this cohort, we modified the tool to
exclude “number of children” and “male HIV 1 uninfected partner un-
circumcised” as used in the original risk scoring tool developed by
Kahle et al (2013) as circumcision is culturally practiced in over 95 %
of Nigerian males.
Results and Discussions: Seventy four percentage of 534 eligible
HESN enrolled had a risk score of 3 (i.e. low risk score) and an overallHIV sero-incidence of 4.2 per 10000 persons month. However HESN
who sero-converted were 4 times more likely to have a risk score of
at least 4 when compared with HESN who remained HIV negative (RR
3.83, fishers exact p = 0.005).
Conclusions: Our data validates the sensitivity of the risk-scoring tool
in our cohort of Nigerian HESN despite the exclusion of male circum-
cision and children in our modified risk score. We recommend the
adaptability of the risk score tool based on prevailing risk factors in
different communities especially with limited resources and the need to
target the most at risk first with available tested prevention programs.
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Background: Adolescents and young adults (AYA) (10-24 years) are sig-
nificantly at risk of HIV acquisition across Southern Africa. The continued
burden of HIV transmission among AYA reflects poor prioritization of
youth-focused and engaged research yielding an inadequate under-
standing of intersecting factors necessary to implement accessible and
effective HIV prevention programs. Use of youth-centred approaches
within HIV research and programming presents a critical opportunity to
engage youth, build capacity, and support youth leadership in the HIV
response.
Methods: AYAZAZI (‘Knowing Themselves’ in Zulu) is a youth-centred,
inter-disciplinary cohort study aiming to link socio-behavioural, struc-
tural, clinical, and biomedical data to understand HIV acquisition risk
among AYA aged 16-24 years living in two study sites: Soweto and
Durban, South Africa. We aim to enroll a cohort of 400 AYA (HIV-negative
or HIV status unknown). AYAZAZI uses a youth-centred approach to en-
gage and retain AYA throughout the research process. A Soweto-based
Adolescent Community Advisory Board and youth engagement committee
provides overall study guidance and oversight. At time of abstract submis-
sion, AYAZAZI Soweto had enrolled 28 males and 35 females. Preparations
are underway to enroll participants in Durban in June 2015.
Youth Engagement Activities: We engaged the expertise and lived experi-
ences of community members in the development of the survey and clin-
ical protocol to ensure youth-appropriate language and priorities. AYA
research assistants from Soweto were hired and trained to support recruit-
ment and to administer surveys. AYA research assistants from Durban will
likewise be hired and trained to do the same. We engaged with several
youth-focused community partners to conduct outreach and raise aware-
ness of AYAZAZI.
Discussion: AYA research assistants and their adult allies will receive
ongoing training to support skill development and participants will
have access to regular knowledge exchange forums to support youth
leadership around HIV knowledge. Youth-centred, inter-disciplinary
approaches require time and patience and the commitment of both
young and older staff. Such research collaborations, however, that en-
gage AYA and adult allies, are needed to better understand the real-
ities of AYA’s and to build local capacity required to prevent HIV
infection and reverse the high HIV risk environment among youth in
South Africa.
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Background: University of Manitoba/ Nairobi is an HIV/STI research cen-
ter that has been in existence since mid 80,s. It has been focusing on
STI/HIV research among sex workers and linkages to general population.
Recently a clinical trial based on Inducing Immune Quiescence as a new
avenue to prevent HIV infection was carried among HIV low risk child-
bearing age women sampled from two communities that are highly
populated with sex workers (neighbors to sex workers) and the commu-
nity aspect was analyzed.
Methods: The HIV Inducing Immune Quiescence (IIQ) clinical trial pre
screened 158 women (neighbors to sex workers) within child bearing
age in a period of one month from Majengo and Ngomongo slums in
Nairobi. Exclusion criteria included HIV/STI positive, pregnancy, lactation,
under age and menopause. The ones who met inclusion criteria were
followed for 3 months and HIV/STI tests carried out monthly.
Results and Discussions: Out of the 158 study participants 9 (5.6 %)
tested HIV positive during pre screening stage, 105 qualified for the
study. None of the 105 sero-converted during the study period.17
(11 %) tested positive for STI. 98 % reported lack of condom use, the
rest reported inconsistent condom use. One percent reported having
two sex partners, while 96 % were married and none of them used con-
doms.
Conclusions: The HIV low risk women living within sex workers popu-
lated slums have high rates of STI which increases the risk of HIV acqui-
sition and transmission. It is a group that should be followed keenly and
treated as a key population. Further research should be done on this
women sex partners/husband to ascertain if they are the regular part-
ners to sex workers due to proximity and the rate of HIV/STI among
their wives.
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Background: A cluster randomized controlled trial in Botswana is testing
the impact on HIV rates in young women of an intervention including
making existing government structural support programmes more ac-
cessible to them. In the first intervention district we conducted an en-
gagement survey of young women.
Methods: Trained female fieldworkers visited all households and inter-
viewed women aged 15-29 years. They asked about awareness of pro-
grammes and experience when applying for support, and shared
information about programmes via video clips and leaflets.
Results: Among 9,396 households visited, 1,838 had someone home
and included at least one female member aged 15-29 years. Among
2,841 young women identified in these households, 1,493 were avail-
able and interviewed (80 refused). Some 15 % of the young women
had been students throughout the last 12 months, 2 % had been in
full time employment throughout, and 40 % had been unemployed
throughout.
Most (81 %) had had sex. In the last 12 months, 16 % of these had sex with
more than one partner, 16 % had a partner more than 10 years older, and
14 % received money or gifts for sex.Awareness of 11 structural support programmes, was variable; for five of
the programmes less than half of the young women had heard of them.
Many did not apply even though they were aware of programmes, and
others applied unsuccessfully. Some 17 % had benefitted from Ipelegeng
(short term employment at minimum wage), 2.5 % from Back to School,
2.3 % from a youth national service programme; rates for all others were
less than 1 %. Most thought the programmes could be useful for young
women, citing making money and improving livelihoods, increasing finan-
cial independence, and building skills and confidence. Problems included
length and complexity of the application process, unhelpful officers, in-
accessible offices, and lack of support or advice about projects. Almost all
expressed interest in workshops to help them use the programmes. Efforts
are underway to integrate programmes and improve logistic support for
officers.
Conclusion: Vulnerable young women (not in education or employment)
are not accessing structural support programmes but are interested to
do so. Implementation research will follow their use and experience of
programmes.
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Background: Early sex and risky behavior may result into new HIV
infections and other consequences, which can be prevented and con-
trolled through improved access to adolescent-friendly services. The
Adolescent-Centered Engagement and Research for Empowerment
(ACERE) is a school-driven multi-level intervention project with in-built op-
erational research (https://www.facebook.com/groups/627284160648195/).
It aims at reducing Sexually Transmitted Infections (STIs) and HIV through
engaging: students, teachers, parents/guardians, municipal, education,
health and law-enforcing authorities; health facilities (to offer a continuum
of HIV prevention and care services), with researchers from UVRI. We
investigated the challenges and opportunities for students to access
adolescent-friendly services.
Methods: In 2013, an Education Officer randomly selected seven second-
ary schools in Entebbe Municipality, Uganda to participate in mixed re-
search methods including Focus Group Discussions (FGDs) and survey. We
conducted 20 gender-specific FGDs (6 for girls, 6 for boys, 4 among female
teachers and 4 in male teachers), using a topic guide and trained facilita-
tors. Each FGD comprised of 10 participants, with adolescents aged 12-19
years. Random participant selection and informed consent were con-
ducted. All FGDs were audio-recorded, transcribed, and stored using Nvivo
8 software.
Results and Discussions: Students reported consequences of pornography,
early sex, STIs, absenteeism, poor class performance, unplanned pregnan-
cies and worrying school drop-out, coupled with illicit drug abuse and al-
cohol. They frequently mentioned: lack of sexual education, co-curricular
activities and tailored health services; judgmental adult health workers;
poor parental support and behavioral modelling. Most teachers reported
their limited knowledge and skills to deliver sexual and life-skills education,
yet parents had negligently left this role to them. However, parents
were not comfortable with teachers talking to their children about
sexuality and reproductive health. The survey revealed that children,
whose parents never supported/encouraged them, were more likely
(58 %) than those supported/encouraged (41 %) to have early sexual
debut (p = 0.02). Children whose parents never listen to them were
more likely (56 %) than those whose parents listen (39 %) to have
early sexual debut (p = 0.004).
Conclusions: Tailor-made sex education material, youth peer-counsellors,
social media skills, , improved parental communication and support, and
co-curricular activities, enabling policies/laws on drugs and alcohol are ur-
gently needed to overcome the challenges encountered.
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Background: The Uganda Virus Research Institute (UVRI) is mandated by
the Ministry of Health to conduct scientific investigations on viral and
other communicable diseases so as to contribute to knowledge, policy
and practice. The Institute reconstructed its website in September 2013
when Facebook/Twitter links were added for interactive research dis-
semination and knowledge sharing purposes.
Methods: With funding from the Adolescent Centered Engagement and
Research for Empowerment (ACERE) study in Entebbe, outreach activ-
ities for adolescents to pose and record questions on HIV, STIs, Medical
Male Circumcision, alcohol and drug abuse were conducted. UVRI re-
cruited a youth counsellor who received these questions and provided
real time researched answers and also coordinated discussions on the
Facebook page.
Results: By November 2014 the UVRI Facebook page clocked to 1000
users. Questions and topics evolved around adolescent attitudes to-
wards pregnancies in the era of AIDS, men’s fear of responsibilities,
whether washing after sex prevents HIV infection, proper use of con-
doms, UVRI experience with the Ebola outbreaks, differences between
Ebola and Marburg and the dynamics of HIV, Ebola and Marburg infec-
tions.
The discussions tried to provide simple responses to those that visited
the website. In the majority of cases users appreciated the simplicity of
the responses and were satisfied with the explanations. The interaction
happened throughout the working hours and the counselor tried to re-
spond outside office hours.
Conclusions: Social media if properly managed can be a great tool in
communicating research findings. It can be used for real time know-
ledge translation targeting interested users. There has been a great turn
up, feedback and interactions from the rest of the world from these Me-
dias, driving more traffic to the UVRI website and reached more audi-
ences than thought. There is need to recruit and train social media
managers in research communication and to develop guidelines on how
to properly manage social media, generate more content and attract
more followers.
Theme 2: HIV Immunology and Genetics – ImGen
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Background: Despite some significant decreases in the HIV prevalence
in the general population, not much is known about the sexual minor-
ities in Zambia. Currently, overall HIV prevalence in the general popula-
tion in Zambia is at 12 %. HIV-1 subtype C is predominant. The HIV
epidemic in Zambia has mainly been known to be confined to the het-
erosexual populations. Though denied, sexual minorities, i.e. lesbians,
gays, bisexuals and transgender exist in Africa. LGBT persons in Zambia
face legal challenges not faced by heterosexuals. This leads to difficulties
they face to access HIV prevention services such as VCT and treatment.For this study, we sought to understand the sexual mixing of the sexual
minorities and the general population by looking at the molecular rela-
tionships of HIV-1 isolates in the two populations.
Objectives: 1) To determine the HIV-1 circulating subtypes amongst sex-
ual minorities in Zambia”; 2) To compare the similarities of HIV-1 isolates
between sexual minorities and the general populations; 3) To describe
the resistance mutations in HIV-1 isolates from in the HIV-1 pol region in
isolates from sexual minorities.
Methods: DBS samples from LGBT and general populations were col-
lected between September 2012 and January 2013. Nucleic acid extrac-
tion from the punched out DBS was performed using the NucliSENS
EasyQ HIV-1 assay EasyQ HIV-1 analyzer platform. PCR was conducted
using the primers published byYang et al (2010). One step RT-PCR was
performed on the extracted viral RNA for the production of viral cDNA
of the HIV-1 pol gene as described by Yang C, McNulty A et al (2010).
PCR products for the sequencing reaction were purified using the
QIAQUICK PCR purification kit. Generated sequences were edited and as-
sembled using the Sequencer version 5 editing tool and analyzed using
the Stanford HIVDB. Subtype identities were determined using the REGA
subtyping tool.
Results and Discussions: Mean viral load was 1353copies/ml (400-
16,666 copies/ml). 93 out 120(81LGBTs + 39 general population) had a
viral load ≥ 400 copies/ml. 19 HIV-1 pol were successfully amplified
(20.4 %). 17 HIV-1 pol successfully sequenced (6 general population &
11LGBTs). All study sequences (pol gene) clustered with HIV-1 subtype C.
The study sequences did not clustered together but mixed with those of
the general population.
No study sequence harbored high-level or intermediate resistance to
NRTIs. One study sequence harbored resistance mutation (K103N) to
EFV and NVP. Three from the General population harbored resistance
to EFV and NVP, while two harbored intermediate resistance to RPV
and ETR. Sexual minorities don’t live in isolation from the general
populations. It is now recognized that they can be a serious reservoir
of the HIV that could compromise HIV control programs.They are
therefore an important target population for HIV prevention.
Conclusions: That the study sequences did not clustered own their
own indicates high levels of bi-sexual relations among the so called
sexual minorities who don’t access the provided for HIV service pro-
gram for the general public for various reasons. Specific strategies
should be developed for this population in order to curb the HIV-1
reservoir problem.Theme 3: Capacity Building for HIV Prevention and
Vaccine Research – CapB
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Background: The establishment of the West African Platform for HIV
Intervention Research (WAPHIR) in 2010 required the unification and
management of HIV cohort resources in Senegal and from our partner
institutions in the Gambia and Guinea Bissau. The setup of the Senegal
WAPHIR Bio-bank supported by a unified database system is important
for supporting planned collaborative intervention research and HIV clin-
ical trial.
Methods: A quality management system (QMS) following the NF S
96-900 and ISO 15189 standards was established to define the Biobank
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according to the ISO 9001 v.2008. The linkage between those processes
and their feasibility were investigated by performing a Biobank pilot
study. Processed samples were logged, stored then, if needed, dissemi-
nated to users by a dedicated software (Item Tracker) and the generated
database was conditionally shared using a Structured Query Language
server.
Results and Discussions: The implanted QMS facilitated the Biobank
activities by written forms (n = 12) and standard operational procedures
(n = 9). The identified processes (n = 10) were linked through a process
mapping with a documentation and communication system. The Bio-
bank approved protocol was conducted using appropriate facilities. Bio-
bank resources were collected in two cohorts and the generated
database contains information from HIV-1 and HIV-2 infected patients
aged ≥ 18 years. For the female sex workers cohort from the Social Hy-
giene Institute, we enrolled 817 patients (754 seronegative and 63 sero-
positive). A number of 1399 samples (plasma, Buffy coats and paxgen)
and 297 PBMC samples were logged and stored respectively in -80 °C
freezer and in liquid nitrogen tank. For the serodiscordant cohort at
Fann hospital, fifty five serodiscordant couples were recruited. Samples
were logged stored in -80 °C freezer and in liquid nitrogen tank respect-
ively for 882 samples (plasma and Buffy coat and 147 paxgen) and for
729 PBMC.
Conclusions: This organized repository with a secured database is an in-
stitutional resource that could serve as a key for good quality research
and to support clinical trials. However, the Biobank activities should be
supported by new HIV projects that will strengthen the HIV platform
and attract international collaboration.
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Background: Canada Africa Prevention Trials Network (CAPT N) initiated
a program in 2010 to create and strengthen sustainable leadership cap-
acity for African sites to conduct HIV Prevention Trials, promote collab-
orative South to South and North South Multidisciplinary HIV Research
initiatives. The Network has 8 sites in Africa and 7 collaborating institu-
tions in Canada.
Methods: The Network’s steering committee gives policy and advisory
services on research and mentorship through regular teleconferences.
Scientists in Africa and Canada have worked together on research
projects as supervisors and mentors. CAPTN provides appropriate
mentorship to graduates of Masters/ PhD and health practitioners
with hands on learning experience in HIV research. The mentor must
provide formal experiential learning environment including the devel-
opment and management of at least one HIV research project for the
mentee.
Results and Discussions: The Network funded circumcision and high
incidence studies on HIV Infection in fishing communities around
Lake Victoria, Uganda. The studies contributed evidence to policy to
the regional ministries of health on treatment as prevention andABCC strategy for HIV prevention. Capacity for seven MSc (2011), one
Ph.D. (2012) and seven mentorships (2014) was built. In 2011 a six
teams Grant on Violence, Gender and Health, worth $8.5 M for re-
searchers and knowledge users at all sites was supported. In March
2012, CAPT-N hosted an Afri-Can forum 1.0 for over 300 HIV researchers
from Africa and Canada to re-think strategies in HIV clinical and vaccine
research. Three young scientists were awarded for their impressive car-
rier growth, with two of them coming from East Africa. Research inter-
vention studies have created awareness resulting in increased number
of people on ART and reduced HIV related deaths. Salary support pro-
vided to institutions facilitated the institutionalization of research in or-
ganizations that were initially service delivery orientated. Challenges
include rampant concurrent sexual relationships leading to new infec-
tions. Also, turnover of scientists to NGOs pose a challenge to timely
implementation of project activities.
Conclusions: There is need to continue complementing, promoting,
strengthening and supporting CAPTN sites in building capacity for the
existing experience and expertise in research between Africa and
Canada through trainings and coordination of research activities.
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Background: HIV is a major health problem globally though Sub Sa-
haran Africa is the worst hit. In 2012, there were 35.3 million people
infected with the virus with more than 75 % being in Sub Saharan Af-
rica. Additionally, 2.3 million new infections occurred in the same
year. As a strategy to address the problem of HIV, a lot of countries
are focusing their efforts on prevention. This saw 26 countries record-
ing 50 % reduction in new infections between 2001 and 2012, while
others lagged behind on this score. In order to achieve the desired
results on the prevention front, all stakeholders need to be fully in-
volved and to double their efforts. As an initiative to build Capacity
for HIV Prevention Research, the TanZamBo organized a two days
workshop in Zambia as part of the advocacy of the TDRC on HIV Pre-
vention Research.
Methods: A workshop was organized to discuss issues related to HIV
prevention research and the role of the community. Participants in-
cluded; community leaders, ordinary community members, commu-
nity health workers, community lay Counselors, staff from the print
and electronic media and sexual minorities. Participants were taken
through modules, given exercises, group discussions on specific
topics and presentations in plenary.
Results and Discussions: Communities perceive research to be a
money spinner, associated with Witchcraft and Satanism. It is a waste
of time as there is no feedback given to the communities. Communi-
ties are reluctant to participate in research due to ignorance, no in-
centives, monotonous questions and lack of community involvement
at inception. These challenges can be addressed by; setting Community
Advisory Committees, proper community engagement and researching
on community generated problems. Solutions lay in engaging commu-
nity leaders early, knowing the community contexts and giving feedback
on results. Additionally, the media should do community sensitization be-
fore, during and after the research and also results dissemination.
Conclusions: Research is a very important tool in HIV prevention. However,
the community should be involved from the start for them to have owner-
ship of the research. The media can play a very important role in sensitiz-
ing people on research and dissemination of results.
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Background: The measurement of HIV viral load (VL) in a feasible and
cheap format is important for efficient monitoring of antiretroviral therapy
(ART) and for understanding HIV pathogenesis before and after treatment.
HIV VL measurement continues to pose a challenge because available HIV-
1 VL assays are expensive to use in resource-limited settings and there is
no commercially validated HIV-2 viral load (VL) assay. The aim of this study
is to develop an accessible HIV-1 and HIV-2 qRT-PCR assay for the viro-
logical monitoring of HIV infected patients in West Africa.
Methods: HIV-1 and HIV-2 primers and probes were designed targeting the
ltr gene using NCBI blast and Primer3, a free online primer design tool. RNA
extraction was done using the QIAamp Viral RNA Mini kit on 200 μl (HIV-1)
and 300 μl (HIV-2) of plasma. The TaqMan Reverse Transcription and TaqMan
Universal master Mix II with UNG were used respectively for the reverse tran-
scription and the real time PCR with the ABI 7500 real time PCR machine.
Results and Discussions: The optimized primers and probe concentrations
were respectively 0.3 and 0.5 μM (HIV-1) and 0.15 and 0.5 μM (HIV-2). The
HIV-1 and HIV-2 qRT-PCR analytical specificities were determined by amplify-
ing the expected products, which were 86 and 75 base pairs respectively for
HIV-1 and HIV-2, without nonspecific targets. The developed qRT-PCR assay
had a dynamic range of 106 to 50 copies. The analytical sensitivity (low limit
of detection) was estimated at 50 copies both for HIV-1 and HIV-2. Amplifica-
tion efficiencies were obtained from the different standard curves and corre-
sponding to PCR efficiencies at 90 % (HIV-1) and 99 % (HIV-2). Characteristics
of the accepted standard curves for HIV-1 and HIV-2 qRT-PCR assays were:
slope (-3.70 to -3.34.) and good linear correlation (R2≥ 0.992).
Conclusions: Optimisation of primer and probe concentrations along with
amplication standisation have permitted ideal standard curves for copy num-
bers of HIV-1 and HIV-2 in a qRT-PCR assay. Other performance characteristics
such as clinical sensitivity and specificity then reproducibility, will be deter-
mined for the assay validation.
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BMC Infectious Diseases 2016, 16(Suppl 2):P13Background: A disproportionate number of women in Sub-Saharan
Africa are infected with HIV but the proportion of men enrolled in anti-
retroviral treatment programs is lower than the proportion of women.
Several studies have reported conflicting effects of sex on HIV-1 infec-
tion. We describe differences in baseline characteristics and assess the
impact of sex on HIV progression among patients at a clinic with many
HIV-2 and dually infected patients.
Methods: The study utilized a retrospective cohort of treatment-naïve
adults at the largest HIV clinic in Guinea-Bissau from June 6, 2005, to
December 1, 2013. Baseline characteristics were assessed and the pa-
tients followed until death, transfer, loss to follow-up, or June 1, 2014.
We estimated the time from the first clinic visit until initiation of ART,
death, or loss to follow-up using Cox proportional hazard models.
Results and Discussions: A total of 5,694 patients were included in the
study, 3,702 women (65 %) and 1,992 men (35 %). Women were more
likely than men to be infected with HIV-2 (19 % vs. 15 %, p < 0.01) or
dually infected with HIV-1/2 (11 % vs. 9 %, p = 0.02). For all HIV types,
women were younger (median 35 vs. 40 years), less likely to have
schooling (55 % vs. 77 %) or to be married (46 % vs. 67 %), and had
higher baseline CD4 cell counts (median 214 vs. 178 cells/μl). Men had a
higher age-adjusted mortality rate (hazard rate ratio (HRR) 1.29, 95 %
confidence interval (CI) 1.09-1.52) and were more often lost to follow-up
(HRR 1.27, 95 % CI 1.17-1.39).
Conclusions: Significant differences exist between HIV-infected men and
women regardless of HIV type. Men seek treatment at a later stage and,
despite better socioeconomic status, have higher mortality and loss to
follow-up than women. This study demonstrates the clear need for in-
creased attention to undiagnosed male HIV patients in Africa, as they
are less likely to seek treatment, putting both their own lives and others’
at risk. Promoting earlier initiation of HIV treatment among men may im-
prove their outcomes.
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Background: An increasing number of HIV infected adolescents are be-
ing transferred from pediatric centers to adult HIV-care. We currently do
not have much information about this population in low prevalence
countries in Africa, such as in Senegal. Our objective was to describe the
demographical, clinical, immunological and virological status of infected
adolescents in transition to adult HIV care in Dakar.
Methods: We used for these analyses follow-up data of HIV-infected
adolescents in transition to adult HIV-care at the Fann Hospital’s
“Center of Clinical Research and Training” in Dakar, Senegal. Descrip-
tive analysis, generalized estimating equation (GEE) and mixed
models were used to assess immunological and virological changes
from baseline to month 24.
Results and Discussions: Twenty-nine infected adolescents were
transitioned since 2011. The median (IQR) of age was 18 years (IQR =
2; min = 15- max =22), and 69 % were male. At baseline or entry, the
median CD4 T-cell count was 478/μL (IQR = 296) and 28 % had prior
CDC category C events. The median Log10 viral load was 3.72 (IQR =
1.22)) and 34 % had undetectable viremia at admission. The median
time of exposure to ART was 6 years (range: 0 – 10 years). Forty one
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line antiretroviral therapy.
During follow-up the median CD4 count went from 478 (IQR = 296)
at entry to 490 (IQR = 274) at month 6, 532 (IQR = 552) at month12,
618 (IQR = 545) at month 18 and 721 (IQR = 550) at month 24, with a
non-significant change the same period. Similarly, the viral load mea-
sures did not worsen during the transition period, with a mean
Log10 viral load measure of 3.07 (STD = 1.41) at entry, 2.51 (STD =
1.11) at month 6, 2.51 (STD = 1.36) at month 12, 3.31 (STD = 1.45) at
month 18, and 2.55 (STD = 1.47) at month 24.
Conclusions: Usually, it is expected that the quality of care will drop
and be disturbed during the transition period of youth from pediatric
to adult care. However, in our clinics at the Fann hospital in Senegal,
the transition and follow-up process can be seen as successful, with
the immunological and virological profiles of adolescents remaining
the same during this sensitive period.
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Background: HIV-1 is characterized by great genetic diversity due to
mutations that occur during viral replication, drug and immunological
pressures. The HIV-1 genetic diversity poses challenge and has implica-
tions on the pathogenesis, transmission, diagnosis, effective vaccine de-
velopment and antiretroviral drug resistance development. The aims of
this study were to characterize and determine mutations associated with
antiretroviral drug resistance among HIV-1 infected children aged less
than 18 months born to HIV-1 infected mothers enrolled in prevention
of mother-to-child transmission services in Northern Tanzania.
Methods: Dried blood spots (DBS) were collected from children born
to HIV-1 infected mothers for HIV-1 early infant diagnosis from Janu-
ary 2011 to December 2012. DBS were tested by PCR at Kilimanjaro
Christian Medical Center (KCMC) Clinical Laboratory. Viral load was
estimated and genotypic resistance testing was determined on sam-
ples with a viral load greater than 400 copies/mL.
Results and Discussions: A total of 640 DBS were collected and
among them 122 were HIV-1 positive by PCR with the mean viral
load of 387 copies/mL. The median age was 12 weeks (IQR 6-28).
Among the positive samples that were eligible for genotyping, se-
quences were successfully generated from 46 samples. HIV-1 subtype
A was predominant (27/46) followed by subtype C (10/46), subtype D
(3/46), CRF10_CD (2/46) and unique recombinant forms (4/46). Geno-
typic resistance mutations were detected in 13 of 46 children (28 %).
The prevalent mutations were Y181C (8/13) and K103N (4/13) associ-
ated with non-nucleoside reverse transcriptase inhibitors (NNRTI) be-
cause of their extensive use. Protease inhibitors are not extensively
used and none associated mutation was detected in the protease
region.
Conclusions: HIV-1 subtype A was more prevalent among vertically
transmitted HIV-1 strains from mother to child as compared to other
co-circulating HIV-1 subtypes in northern Tanzania. Mutations associ-
ated with resistance to non-nucleoside reverse transcriptase were
more predominant due to extensive use of the drug in theprevention of mother to child HIV-1 transmission. Resistance to anti-
retroviral drug resistance testing may be warranted among children
with vertically transmitted HIV-1 infection before starting highly ac-
tive antiretroviral treatment.P16
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Background: Growth is a good indicator of the overall well being of a
child. Growth failure or deceleration has been closely associated with in-
creased health problems and sometimes death in infants. We reported
earlier that infants born to HIV infected mothers are twice at risk of
death mainly due to infectious morbidities. In this respect, growth moni-
toring particularly in HIV exposed children is an important tool to ensure
timely and appropriate care for these children.
Methods: A cohort of HIV exposed (HIV-EU) marched with HIV un-
exposed (HIV-N) infants were enrolled at birth and followed up
during 8 study visits in 52 weeks in Jos Nigeria. Baseline assess-
ment consisted of gestational age, physical examination, an-
thropometrics, noting of gross congenital anomalies and birth
complications. Newborns with birth complications were excluded.
Anthropometrics, co-morbidities and feeding practices were eval-
uated at each study visit.
Results and Discussions: Two hundred and thirty six HIV-EU and 76
HIV-N infants were enrolled. At birth, HIV-EU infants were smaller in
weight, length and head circumference than HIV-N infants (mean
weight 2959 g, SD 398 vs. 3189 g, SD 529, p value 0.0001; mean
length 47.1 cm, SD 3.13 vs. 48.6 cm, SD 3.69, p value 0.0005; and
mean head circumference 34.3 cm, SD 1.59 vs. 35.2 cm, SD 1.72, p
value 0.0001). Although, there was impaired weight gain and head
circumference increment in HIV-EU compared with HIV-N infants, the
length of HIV-EU caught up with that of HIV-N infants by 15 weeks.
The proportion of HIV-EU that were exclusively breast-fed for the first
6 months was comparable to HIV-N infants (209/236, 88.56 % vs. 68/
76, 89.66 % p value 0.826.
Conclusions: Our study seem to indicate that breastfeeding which is
the usual practice in Nigeria could improve nutrition and correct lin-
ear growth faltering in infants. We plan to continue to assess devel-
opmental milestones to determine the consequences of early-
impaired head circumference increment, weight and length observed
in HIV-EU infants since growth faltering in early childhood has been
associated with increased risks of glucose intolerance and cardiovas-
cular diseases in adulthood.
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Background: The N348I mutation in the connection subdomain of HIV-1
Reverse Transcriptase (RT) has been reported to reduce susceptibility to
Nevirapine (NVP), Efavirenz (EFV) and Zidovudine (AZT), and is frequently
selected in HIV-1 patients experiencing virologic failure. The frequency
of this mutation is under reported as most of the studies only report RT
mutations up to position 335. We here sort to investigate the frequency
of the N348I mutation in HIV-1 subtype C infected patients in Botswana
failing different antiretroviral therapy regimens as there is no data on
the prevalence of this mutation in patients failing cART in Botswana.Methods: HIV-1 drug resistance genotyping was done on samples from
two previous clinical trials conducted at Botswana Harvard Partnership
investigating the efficacy of different ART regimens. Plasma samples
from 43 patients who experienced virologic failure from the two studies
were available for genotyping. Virologic failure was defined as confirmed
plasma HIV-1 RNA greater than 400 copies/mL at 6 months post HAART
initiation or any time after initial virologic suppression. A PCR assay cov-
ering position 348 of HIV-1 RT connection subdomain was optimized
and used to amplify the region followed by big dye sequencing of the
PCR product. The RT sequences were analyzed for the N348I resistance
mutation using the Stanford HIV drug resistance database.
Results and Discussions: Thirty-four of the 43 (79.1 %) virologic failure
samples were successfully genotyped. Amongst the 34, 9(26.5 %) were
found to harbor the N348I mutation. The N348I mutation emerged in 10 %
of patients failing Zidovudine (AZT) containing cART and 33.3 % of partici-
pants failing regimens containing Nevirapine (NVP) or Efavirenz (EFV).
Conclusions: We found a frequency of 26.5 % for N348I mutation among
HIV-1C patients experiencing virologic failure in Botswana. The association
of the N348I mutation with virologic failure in this population warrants fur-
ther investigation but in this cohort it seemed to be more closely linked
with NNRTI failure than with AZT failure. The kinetics of the mutation in re-
lation to other RT mutations also needs to be investigated to better under-
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